The role of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based drugs for type 2diabetes.In recent years,it has been proven in clinical practices that GLP-1 receptor agonists have protection effect beyond anti-hyperglycemic effects,such as improvement of non-alcoholic fatty liver disease (NAFLD).The cogent evaluation,understanding,and exploration of therapeutic effect and mechanism of GLP-1 receptor agonists in NAFLD are important.Besides,it would be of great significance to identify pathogenesis of diabetes,its correlation with NAFLD,and the development of new drugs.This article briefly reviews the therapeutic effect of GLP-1 receptor agonists on NAFLD. Key words: Non-alcoholic fatty liver disease;  Glucagon-like peptide-1;  Diabetes mellitus, type 2; Glucagon-like peptide-1 receptor agonists